NCT06810960 A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease
| NCT ID | NCT06810960 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Eisai Korea Inc. |
| Condition | Alzheimer's Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2025-02-24 |
| Primary Completion | 2029-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2025-02-24 with a primary completion date of 2029-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary purpose of this study is to evaluate safety of LEQEMBI in the real-world clinical setting as reported by events of amyloid-related imaging abnormalities (ARIA)-edema (ARIA-E), ARIA-hemosiderin deposition (ARIA-H), symptomatic ARIA-E, symptomatic ARIA-H, and intracerebral hemorrhage (ICH) greater-than 1 centimeter (cm) in patients treated with LEQEMBI.
Eligibility Criteria
Inclusion Criteria: * Enrolled in JOY-ALZ before the decision to treat with LEQEMBI * The clinical decision to treat with LEQEMBI has already been made * Provides written informed consent for the use of medical information to be shared with Eisai Korea Inc. Exclusion Criteria: * Currently participating in an interventional clinical study
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06810960 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Alzheimer's Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06810960 currently recruiting?
Yes, NCT06810960 is actively recruiting participants. Contact the research team at s-kwon@eisaikorea.com for enrollment information.
Where is the NCT06810960 trial being conducted?
This trial is being conducted at Nutley, United States.
Who is sponsoring the NCT06810960 clinical trial?
NCT06810960 is sponsored by Eisai Korea Inc.. The trial plans to enroll 3,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.